456 related articles for article (PubMed ID: 32473388)
1. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.
Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H
Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388
[TBL] [Abstract][Full Text] [Related]
2.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
3. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.
Sader HS; Mendes RE; Pfaller MA; Shortridge D; Flamm RK; Castanheira M
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061754
[TBL] [Abstract][Full Text] [Related]
4.
Karlowsky JA; Kazmierczak KM; de Jonge BLM; Hackel MA; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630192
[TBL] [Abstract][Full Text] [Related]
5. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
7. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
8. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study.
Wei J; Zou C; Wang D; Huang A; Niu S
J Glob Antimicrob Resist; 2020 Sep; 22():448-451. PubMed ID: 32387260
[TBL] [Abstract][Full Text] [Related]
9. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
[TBL] 
